Browse All Available Clinical Trials
Join Now to be Notified of New Clinical Trials
View Information and Clinical Trials for Other Conditions
Herpes Zoster
Herpes zoster, colloquially known as
shingles, is the reactivation (from the nerve cell body in the sensory ganglion of a segment of the
spinal cord) of varicella zoster virus (VZV, primary infection of which leads to chickenpox), one of the Herpesviridae group, leading to a crop of
painful blisters over the area of a dermatome. In Italy and in Malta, it is sometimes referred to as "St. Anthony's fire", although that name usually
refers to ergotism. Shingles, or herpes zoster, is a neurological disease, affecting the nervous system with or without the appearance of a rash
on the skin.
Treatment is generally with antiviral drugs such as acyclovir (Zovirax), or prodrugs such as famciclovir (Famvir), or valacyclovir (Valtrex). For the
antiviral drugs to be most effective, patients should begin taking them as soon as possible after the appearance of the rash, within 12 to 72 hours for
maximum efficacy.
Current Research
For current research articles click
- here
Signs and Symptoms
The earliest symptoms (constituting the prodrome) of shingles include headache, sensitivity to light, fever, and malaise, all of which may, within
one to several days, be followed by itching, tingling, and
pain which may be extreme in the distribution of the affected nerve, where the rash will
later develop. This
pain can be characterized as stinging, tingling, aching, numbing, or throbbing, and can be pronounced with quick stabs of intensity.
During this phase, herpes zoster is frequently misdiagnosed as other diseases with similar symptoms, including heart attacks and renal colic. Some
patients may have these symptoms without developing the characteristic rash. This situation, known as "zoster sine herpete," can delay diagnosis and
treatment.
The initial phase is followed by development of the characteristic skin rashes of herpes zoster. The skin lesions begin as a rash, similar to hives,
that follows a distribution near dermatomes, commonly occurring in a strip or belt-like pattern. The rash evolves into vesicles or small blisters filled
with serous fluid. The vesicles are generally painful, and their development is often associated with the occurrence of
anxiety and further
flu-like
symptoms, such as fever, tiredness, and generalized
pain. The vesicles eventually become hemorrhagic (filled with blood), and crust over within seven
to 10 days. As the crusts fall off, patients are commonly left with scarring and pigmented skin.
Shingles cannot be passed from one person to another. However, the virus that causes shingles, VZV, can be spread from a person with active shingles
to a person who has never had chickenpox through direct contact with the rash. The person exposed would then develop chickenpox, not shingles. The
virus is not spread through sneezing, coughing or casual contact. A person with shingles can spread the disease when the rash is in the blister-phase.
Once the rash has developed crusts, the person is no longer contagious. A person is not infectious before blisters appear or with post-herpetic
neuralgia (pain after the rash is gone).
Chickenpox virus can remain dormant for decades, and does so inside the ganglion of the spinal cord. As the virus is reactivated it spreads down
peripheral nerve fibers and produces intense
pain. The blisters therefore only affect one area of the body and do not cross the midline. They are most
common on the torso, but can also appear on the face (where they are potentially hazardous to vision) or other parts of the body.
Causes
Shingles can only arise in individuals who have had previous exposure to chicken pox (varicella zoster). Individuals develop shingles for many different
reasons, most of which are thought to be a result of events which depress the immune system, such as aging, severe emotional stress, severe illness,
immunosuppression or long-term use of corticosteroids. However, the cellular and immunological events that lead to reactivation are poorly understood.
There have been recorded cases of outbreaks occurring due to unmanaged stress or other stresses to the skin such as pinching in more sensitive areas of
the skin (nipples, ears, and underarms), scratching, or biting.
Pathophysiology
The causative agent for herpes zoster is varicella zoster virus (VZV). Most people are infected with this virus as a child, as it causes chickenpox.
The body eliminates the virus from the system, but it remains dormant in the ganglia adjacent to the spinal cord (called the dorsal root ganglion) or
the ganglion semilunare (ganglion Gasseri) in the cranial base.
Generally, the immune system suppresses reactivation of the virus. In the elderly, whose immune response generally tends to deteriorate, as well as in
those patients whose immune system is being suppressed, this process fails. (Some researchers speculate that sunburn and other, unrelated stresses that
can affect the immune system may also lead to viral reactivation.) The virus starts replicating in the nerve cells, and newly formed viruses are
carried down the axons to the area of skin served by that ganglion (a dermatome). Here, the virus causes local inflammation in the skin, with the
formation of blisters.
The
pain characteristic of herpes zoster is thought to be due to irritation of the sensory nerve fibers in which the virus reproduces.
Diagnosis
The diagnosis is visual; very few other diseases mimic herpes zoster, especially in the localization of the rash, which is otherwise quite similar in
appearance and initial effect to that of poison oak or poison ivy (although it may not be accompanied by the intense itching so characteristic of
those rashes).
In case of doubt, diagnostic tests can be performed. Such lab tests may be necessary because, depending on the affected sensory nerve, the
pain that
is experienced before the onset of the rash may be misdiagnosed as pleurisy, myocardial infarction,
appendicitis, cholelithiasis, or a
migraine headache.
Fluid from a blister may be taken so the cells can be analyzed in a medical laboratory. While looking at the cells obtained from the blister, those
infected with the
herpes virus will appear very large and contain many dark nuclei. A physician can also take a viral culture of a fresh lesion, or
perform a microscopic examination of the blister base called a Tzanck preparation. In a complete blood count there may be an elevated number of white
blood cells, which is an indirect sign of infection. There may also be a rise in the antibody to the virus, which would also give indication of the
virus’ reactivation.
Treatment
Currently, there is no cure available for Herpes zoster, nor a treatment to effectively eliminate the virus from the body. However, there are some
treatments that can mitigate the length of the disease and alleviate certain side effects.
Antiviral Drugs
Acyclovir (an antiviral drug) inhibits replication of the viral DNA, and is used both as prophylaxis (e.g., in patients with
AIDS) and as therapy for
herpes zoster. Other antivirals are valacyclovir and famciclovir. During the acute phase, oral acyclovir should be given. Use of acylovir is most
effective in moderating the progress of the symptoms, and in preventing post-herpetic neuralgia, if started within 24 to 72 hours of the onset of
symptoms, so medical care should be obtained as soon as the condition is recognized. Immunocompromised patients may respond best to intravenous
acyclovir. In patients who are at high risk for recurrences, an oral dose of acyclovir, taken twice daily, is usually effective. It is also reported
that the amino acid lysine inhibits the replication of herpes zoster.
Other Drugs
Cimetidine, a common component of over-the-counter heartburn medication, has been shown to lessen the severity of herpes zoster outbreaks in several
different instances. This usage is considered an off-label use of the drug. In addition, cimetidine and probenecid have been shown to reduce the renal
clearance of aciclovir. The study showed these compounds reduce the rate, but not the extent, at which valaciclovir is converted into aciclovir.
Renal clearance of aciclovir was reduced by approximately 24% and 33% respectively. In addition, respective increases in the peak plasma concentration
of acyclovir of 8% and 22% were observed. The authors concluded that these effects were "not expected to have clinical consequences regarding the
safety of valaciclovir". Due to the tendency of aciclovir to precipitate in renal tubules, combining these drugs should only occur under the supervision
of a physician.
Complementary Therapies
Digestive Enzymes are available on script and in some over the counter preparations. Before the availability of antivirals, oral pancreatic enzyme
therapy in shingles was used in some countries and later subjected to clinical and scientific research. A large scale multi-centre clinical study,
using an oral preparation of such enzymes, has shown promising results. The results of another clinical study support the concept that oral
enzyme therapy is beneficial in diseases characterized in part by TGF-beta overproduction that included shingles patients. TGF-B has also been
found higher in instances of VZV.
Prognosis
The rash and
pain usually subside within 3 to 5 weeks. Many patients develop a painful condition called postherpetic neuralgia, which is often difficult
to manage. In some patients, herpes zoster can reactivate subclinically, with pain in a dermatomal distribution without rash. This condition is known
as zoster sine herpete, and may be more complicated, affecting multiple levels of the nervous system and causing multiple cranial neuropathies,
polyneuritis, myelitis, or aseptic
meningitis. Sometimes serious effects including partial facial paralysis (usually temporary), ear damage, or
encephalitis may occur. Shingles on the upper half of the face (the first branch of the trigeminal nerve) may result in eye damage and require urgent
ophthalmological assessment. Ocular complications occur in approximately one half of patients with involvement of the ophthalmic division of the
trigeminal nerve. These complications include mucopurulent conjunctivitis, episcleritis, keratitis and anterior uveitis. Cranial nerve palsies of the
third, fourth and sixth cranial nerves may occur, affecting extraocular motility.
Since shingles is a reactivation of a virus contracted previously—often decades earlier—it cannot be induced by exposure to another person with
shingles or chickenpox. Those with active blisters, however, can spread chickenpox to others who have never had that condition and who have not been
vaccinated against it.
Prevention
Zostavax is a vaccine developed by Merck & Co. which has proven successful in preventing half the cases of herpes zoster in a study of 38,000 people who
received the vaccine. The vaccine also reduced by two-thirds the number of cases of postherpetic neuralgia. However, prior to the vaccine, it
has long been known that adults received natural immune boosting from contact with children infected with varicella. This helped to suppress the
reactivation of herpes zoster. In Massachusetts, herpes zoster incidence increased 90%, from 2.77/1000 to 5.25/1000 in the period of increasing
varicella vaccination 1999-2003. The effectiveness of the varicella vaccine itself is dependent on this exogenous (outside) boosting mechanism.
Thus, as natural cases of varicella decline, so has the effectiveness of the vaccine.
The intake of micronutrients, including antioxidant vitamins, A, C, E and vitamin B, as well as fresh fruit, may reduce the risk of developing shingles.
In one study, patients who consumed less than one serving of fruit a day had three times the risk as those who consumed over three servings per day.
For those aged 60 or more, micronutrient and vegetable intake had a similar lowering of risk. A recent study evaluated the effects of two types of
behavioral intervention, Tai Chi and health education, on healthy adults, who, after 16 weeks of the intervention, were vaccinated with VARIVAX, a live
attenuated Oka/Merck Varicella zoster virus vaccine.
Epidemiology
Prior to implementation of the universal varicella vaccination program in the U.S., incidence of shingles increased with advancing age in association
with a progressive decline in immunity to varicella-zoster virus. Shingles incidence is highest in persons who are over age 55, as well as in
immunocompromised patients regardless of age group. The incidence rate of Herpes zoster in persons aged 65 or older is approximately 19 per 1000
individuals per year in the US. The incidence in whites of this age group is approximately 3.5 times higher than in hispanics.It can also be seen in
immunocompetent individuals undergoing severe emotional stress.
(adapted from Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Shingles)
Healthcare Costs of Acute and Chronic Pain Associated with a Diagnosis of Herpes Zoster
Authors: Dworkin RH, White R, O'connor AB, Baser O, Hawkins K.
Departments of Anesthesiology, and Neurology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA
OBJECTIVES: To determine the healthcare costs of acute and chronic
pain associated with herpes zoster. DESIGN: Retrospective cohort analysis. SETTING:
Inpatient and outpatient care. PARTICIPANTS: Patients were selected from Medicare, commercial insurance, and Medicaid claims databases if they had a
diagnosis of herpes zoster or postherpetic neuralgia (PHN) or were prescribed analgesics after a diagnosis of herpes zoster (possible PHN) and were
matched to controls for demographic and clinical factors using propensity scores. MEASUREMENTS: One-year excess healthcare expenditures attributable to
herpes zoster
pain or PHN were calculated for inpatient, outpatient, and prescription drug services. RESULTS: For the Medicare cohort, the average
excess cost per patient was $1,300 in the year after a diagnosis of herpes zoster with 30 days or fewer of analgesic use and ranged from $2,200 to $2,300
per patient with PHN or possible PHN. Patients with possible PHN were 53% more prevalent than patients with PHN in the Medicare cohort and accounted for
half of all excess expenditures. Findings were similar in the younger cohorts with commercial insurance and Medicaid except that costs attributable to
PHN and possible PHN were higher, and patients with possible PHN were three to five times as prevalent as patients with PHN. CONCLUSION: Healthcare costs
associated with PHN were substantially greater than those associated with herpes zoster
pain that resolved within 30 days. The data suggest that as many
as 80% of patients with PHN may not be diagnosed with PHN and that these patients account for at least half of PHN expenditures.
Journal: J Am Geriatr Soc. 2007 Aug;55(8):1168-75.
Adapted from PubMed; click here to access full journal article.
Zoster Vaccine Live
Authors: Kockler DR, McCarthy MW.
Drug Information Services, Virginia Commonwealth University Health System-Medical College of Virginia Hospitals, and the Virginia Commonwealth University
School of Pharmacy, Charlottesville, Virginia 23298-0042, USA. dkockler@mcvh-vcu.edu
Herpes zoster is a neurocutaneous disease caused by the varicella-zoster virus and is associated with significant morbidity and long-term sequelae in
older adults. Until recently, treatment options for these complications have been primarily targeted at disease state management and symptom relief.
Zoster vaccine live is the first vaccine approved for the prevention of herpes zoster. The vaccine was approved by the United States Food and Drug
Administration for adults aged 60 years or older. Results of the Shingles Prevention Study demonstrated that in older individuals, administration of
zoster vaccine live reduces the burden of illness associated with herpes zoster by 61.1%, the frequency of herpes zoster
pain and discomfort by 51.3%,
and the frequency of postherpetic neuralgia by 66.5%. Overall, adverse events reported in clinical trials of zoster vaccine live were classified as mild.
Events that occurred more frequently in zoster vaccine live recipients than in placebo recipients included injection site reactions, headache, respiratory
infections, fever,
flu syndrome, diarrhea, rhinitis, skin disorders, respiratory disorders, and asthenia. The Centers for Disease Control and Prevention's
Advisory Committee on Immunization Practices recently recommended universal vaccination for those 60 years of age and older, including those who have
experienced previous episodes of shingles.
Journal: Pharmacotherapy. 2007 Jul;27(7):1013-9.
Adapted from PubMed; click here to access full journal article.
Open-Label Study of Valacyclovir 1.5 g Twice Daily for the Treatment of Uncomplicated Herpes Zoster in Immunocompetent Patients 18
Years of Age or Older
Authors: Madkan VK, Arora A, Babb-Tarbox M, Aboutlabeti S, Tyring S.
Department of Dermatology, University of Texas School of Medicine, Center for Clinical Studies, Houston, TX 77030, USA
BACKGROUND: Herpes zoster (shingles) is a common disease caused by a reactivation of the latent varicella-zoster virus (chickenpox), which resides in the
dorsal root ganglia. Valacyclovir HCl, the L-valyl ester of acyclovir, is an antiviral drug that is used to accelerate the resolution of the herpes
zoster rash and associated
pain and reduce the duration of postherpetic neuralgia. OBJECTIVE: To demonstrate the safety and efficacy of oral valacyclovir
1.5 g twice daily (bid) for the treatment of uncomplicated herpes zoster in immunocompetent patients over 18 years of age. The dosing schedule of bid
versus three times daily is desirable for enhancing patient compliance and to subsequently reduce the incidence of viral resistance. METHODS: One
treatment group of 125 patients was administered oral valacyclovir 1.5 g bid for 7 days. Administration of the first dose occurred within 72 hours after
onset of rash. Patients were seen and assessed for cutaneous healing, zoster-associated
pain (ZAP), and/or zoster-associated abnormal sensations (ZAAS).
Patients under 50 years of age were followed for 4 weeks and patients 50 years of age and older were followed for a total of 24 weeks. Patients >or=
50 years were also asked to record a daily diary on pain and abnormal sensations throughout the 24-week study period. Responses to resource use and
quality of life questions were also collected. Safety was monitored by means of routine hematologic and biochemical assessments and reporting of adverse
experiences. RESULTS: Data from this study were compared with historical control groups both for three times daily antiviral therapy and for placebo.
The results showed that twice-daily dosing was as safe and effective as three times daily dosing for the reduction of ZAP and ZAAS. Adverse-effect
profiles were similar between the two different regimens, and both treatment groups showed better outcomes than the historical placebo group. Because
it is standard of care to administer antivirals for the treatment of acute herpes zoster, a placebo-controlled trial is not possible, necessitating the
use of historical controls. CONCLUSION: Oral valacyclovir 1.5 g bid is safe and effective for the treatment of uncomplicated herpes zoster in
immunocompetent patients over 18 years of age. Twice-daily dosing may help increase patient compliance and therefore increase the effectiveness of
treatment of the acute herpes zoster rash and the prevention of ZAP.
Journal: J Cutan Med Surg. 2007 May-Jun;11(3):89-98.
Adapted from PubMed; click here to access full journal article.
Management Strategies for Herpes Zoster and Postherpetic Neuralgia
Authors: Galluzzi KE.
Philadelphia College of Osteopathic Medicine, 4190 City Avenue, Philadelphia, PA 19131-1633, USA. katherineg@pcom.edu
Evidence-based strategies for the management of herpes zoster and postherpetic neuralgia (PHN) include the use of antiviral agents in acute zoster and
specific analgesics in PHN. Antiviral agents are effective in reducing the severity and duration of acute herpes zoster when given within 72 hours of
rash onset, but they do not prevent PHN. Anticonvulsants, tricyclic antidepressants, opioids, and topical treatment modalities such as lidocaine-containing
patches and capsaicin cream offer moderate
pain relief to some patients with PHN, but they may be associated with adverse events that limit their use.
Therefore, prevention of herpes zoster and PHN with prophylactic vaccination using the zoster virus vaccine is an effective strategy to reduce the
morbidity of these conditions. Treatment modalities are available, however, that may shorten the duration of acute herpes zoster and alleviate the pain
of PHN.
Journal: J Am Osteopath Assoc. 2007 Mar;107(3 Suppl 1):S8-S13.
Adapted from PubMed; click here to access full journal article.
The Burden of Herpes Zoster and Postherpetic Neuralgia in the United States
Authors: Weaver BA.
Armor Correctional Health Services, Hillsborough County Jail Medical Clinic, 520 Falkenburg Road, Tampa, FL 33619, USA. bethanyg@myuw.net
Herpes zoster (shingles), a painful and disabling disease, affects an estimated 1 million individuals in the United States annually and results in
significant morbidity, lost productivity, and diminished quality of life. Herpes zoster constitutes the reactivation of varicella-zoster virus (VZV),
the same virus that causes chickenpox. After resolution of chickenpox, VZV remains dormant in dorsal root ganglia. Varicella-zoster-specific cell-mediated
immunity wanes naturally with advancing age or earlier in the setting of an altered immune status, which can result in the reactivation of VZV as
herpes zoster. The
pain associated with the rash caused by herpes zoster is often described as burning, stabbing, itching, or aching. Postherpetic
neuralgia, the most common complication of herpes zoster, occurs after the zoster rash has resolved, affecting up to a third of patients. Herpes zoster
is associated with significant morbidity, especially in the elderly. Herpes zoster is both more common and more severe among older adults. In both acute
herpes zoster and postherpetic neuralgia,
pain is the primary cause of morbidity.
Journal: J Am Osteopath Assoc. 2007 Mar;107(3 Suppl 1):S2-7.
Adapted from PubMed; click here to access full journal article.
Chickenpox Exposure and Herpes Zoster Disease Incidence in Older Adults in the U.S.
Authors: Chaves SS, Santibanez TA, Gargiullo P, Guris D.
Viral Diseases Division, Centers for Disease Control and Prevention,1600 Clifton Rd., NE; MS-A-47, Atlanta, GA, 30333, USA. schaves@cdc.gov
OBJECTIVES: Exposure to varicella zoster virus through close contact with people with chickenpox was suggested to boost specific immunity, reducing the
risk of herpes zoster (HZ). Since the introduction of the varicella immunization program in the US in 1995, varicella morbidity has decreased
substantially. This article examines incidence and risk factors associated with self-reported HZ disease and whether exposure to chickenpox within
the previous decade reduces the risk of shingles in this age group. METHODS: In 2004, a national random-digit dial telephone survey was used to obtain
information on self-reported HZ disease, demographic characteristics, and exposure to children with chickenpox in the past decade. National estimates
of the incidence of shingles disease were calculated. RESULTS: Incidence rate of self-reported HZ was 19 per 1,000 population per year. White individuals
were 3.5 times more likely to report shingles than Hispanic individuals (p<0.01). Previous exposure to chickenpox did not protect against HZ disease
in this population. Seven percent of adults > or =65 years of age reported exposure to children with chickenpox in the past decade. CONCLUSIONS:
Incidence of HZ among individuals > or =65 years of age in the U.S. may be higher than previously described in the literature, with whites being at
higher risk for the disease. Currently, the potential contribution of exposure to chickenpox as a mechanism for maintaining cell-mediated immunity
against HZ may be limited to a small percentage of the population. Vaccination against HZ may represent the best means of decreasing this disease
burden.
Journal: Public Health Rep. 2007 Mar-Apr;122(2):155-9.
Adapted from PubMed; click here to access full journal article.
Join Now - Become a free member and get notified about studies in your area when they become available.
Browse Our Current Studies - Look over all of our current studies being conducted throughout the United States.
View Information and Clinical Trials for Other Conditions - Access all of our health-related content.